Literature DB >> 4722572

Plasma growth hormone and insulin response to levodopa and amantadine.

O Kytömäki, R Nousiainen, A Pekkarinen, U K Rinne, M Viljanen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4722572     DOI: 10.1007/BF01244667

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


× No keyword cloud information.
  18 in total

1.  Treatment of Parkinson's disease with amantadine and L-Dopa.

Authors:  U K Rinne; V Sonninen; T Siirtola
Journal:  Eur Neurol       Date:  1972       Impact factor: 1.710

2.  Influence of levodopa on serum levels of anterior pituitary hormones in man.

Authors:  G Boden; L E Lundy; O E Owen
Journal:  Neuroendocrinology       Date:  1972       Impact factor: 4.914

3.  Possible role of dopamine as transmitter to promote discharge of LH-releasing factor.

Authors:  H P Schneider; S M McCann
Journal:  Endocrinology       Date:  1969-07       Impact factor: 4.736

4.  Postmenopausal bleeding: another side-effect of levodopa.

Authors:  C Kruse-Larsen; K Garde
Journal:  Lancet       Date:  1971-04-03       Impact factor: 79.321

5.  L-Dopa treatment in Parkinson's Disease.

Authors:  U K Rinne; V Sonninen; T Siirtola
Journal:  Eur Neurol       Date:  1970       Impact factor: 1.710

6.  Turnover changes in the tubero-infundibular dopamine neurons during the ovarian cycle of the rat.

Authors:  K Ahren; H Fuxe; L Hamberger; T Hökfelt
Journal:  Endocrinology       Date:  1971-06       Impact factor: 4.736

7.  Castration, sex hormones, and tubero-infundibular dopamine neurons.

Authors:  K Fuxe; T Hökfelt; O Nilsson
Journal:  Neuroendocrinology       Date:  1969       Impact factor: 4.914

8.  Growth hormone and insulin levels in weanling rats with ventromedial hypothalamic lesions.

Authors:  L A Frohman; L L Bernardis
Journal:  Endocrinology       Date:  1968-06       Impact factor: 4.736

9.  Blood levels of FSH, LH, TSH, and GH in parkinsonian patients before and during L-dopa treatment.

Authors:  P O Lundberg
Journal:  Acta Neurol Scand       Date:  1972       Impact factor: 3.209

10.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

View more
  2 in total

Review 1.  Weight loss in Parkinson's disease.

Authors:  Kenichi Kashihara
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

2.  COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.

Authors:  T Keränen; A Gordin; M Koulu; M Scheinin; S Antila; S Sundberg; T Wikberg
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.